Last reviewed · How we verify
NCT04650542
Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects
Phase 1 trial testing HBI-3000 in Drug-drug Interaction in 39 participants. Completed in 13 August 2021.
13 August 2021
Quick facts
| Lead sponsor | HUYABIO International, LLC. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 39 |
| Start date | 21 February 2021 |
| Primary completion | 13 August 2021 |
| Estimated completion | 13 August 2021 |
| Sites | 2 locations across United States, Australia |
Drugs / interventions tested
- HBI-3000 — full drug profile →
- Paroxetine — full drug profile →
Conditions studied
- Drug-drug Interaction — all drugs for Drug-drug Interaction →
Sponsor
HUYABIO International, LLC. — full company profile →
Who can join
Adults 18 to 50, any sex, with Drug-drug Interaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04650542
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HBI-3000
Trials testing the same drug.
- NCT04680026 — A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF) · Phase 2 · active not recruiting
- NCT03397641 — A Phase 1 Study of HBI-3000 · Phase 1 · completed
Other recruiting trials for Drug-drug Interaction
Currently open trials in the same condition.
- NCT06381375 — Drug-drug Interactions With Anti-tuberculous Drugs · recruiting
- NCT06682325 — Pharmaco-proteomic Platform to Evaluate Drug Interactions in Liver Transplant Patients · recruiting
- NCT05044962 — Kuwa Free! - Live Free! · NA · recruiting
Other HUYABIO International, LLC. trials
Trials by the same sponsor.
- NCT05485974 — A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation · Phase 1 · active not recruiting
- NCT05141357 — A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer · Phase 2 · terminated
- NCT05163028 — A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations · Phase 1 · active not recruiting
- NCT04680026 — A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF) · Phase 2 · active not recruiting
- NCT03397641 — A Phase 1 Study of HBI-3000 · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04650542 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by HUYABIO International, LLC.
- Last refreshed: 15 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04650542.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing